Exploring the impact of conventional and targeted DMARDs on body weight in patients with PsA
The rate of weight gain significantly decreases following the initiation of IL-17i, IL-23i and csDMARDs in PsA. Overall, TNFi and IL12/23i use is associated with weight gain, while apremilast with weight loss.
Authors
- Sheng Gao (ORCID: https://orcid.org/0000-0002-8622-5694)
- Denis Poddubnyy (ORCID: https://orcid.org/0000-0002-4537-6015)
- Fadi Kharouf (ORCID: https://orcid.org/0000-0002-3540-0341)
- Dafna D. Gladman (ORCID: https://orcid.org/0000-0002-9074-0592)
- V. Carrizo Abarza
- Richard J. Cook (ORCID: https://orcid.org/0000-0002-1414-4908)
- Pankti Mehta (ORCID: https://orcid.org/0000-0001-9134-0999)
- Vinod Chandran (ORCID: https://orcid.org/0000-0002-8297-0275)
Institutions
- University of Waterloo (CA)
- University of Toronto (CA)
- Arthritis and Rheumatism Associates (US)
- Krembil Foundation (CA)
- Krembil Research Institute
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1093/rheumatology/keaf277
- Citations
- 1
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.67